Don Listwin, Canary FoundationMr. Listwin is the Chairman of the GenoLogics board and founder and chairman of Canary Foundation, the United States’ only non-profit organization devoted exclusively to early detection of cancer. A 25-year veteran of the technology industry - he was CEO of Openwave and had been the #2 executive at Cisco Systems – Mr. Listwin walked away from his high profile technology career and launched Canary Foundation as a way to address the imbalance in cancer research. Canary Foundation has assembled a science team that includes some of the world's leading cancer researchers to attack early detection in a new, collaborative approach. Canary Foundation's ultimate goal is to speed development of biomarkers that can detect the presence of cancers at their very earliest stage, when they are most treatable and chances for full recovery are greatest. Mr. Listwin also serves on the boards of Sana Security, Stratos Biosciences, and the Listwin Family Foundation. He is also a member of the Board of Trustees at the Fred Hutchinson Cancer Research Center. A native of Canada, Mr. Listwin holds a B.S. in electrical engineering and an honorary doctorate of law from the University of Saskatchewan. |
Charles (Chad) P. Waite Jr., OVP Venture PartnersMr. Waite has more than 25 years of experience in both the management and investment sides of emerging growth companies. In 1987, he left his post as General Partner at Hambrecht & Quist Venture Partners to join OVP Venture Partners. Prior to that, he was in marketing and sales management at Cobe Laboratories, Inc. in its cardiovascular medical products division. Mr. Waite holds an AB in History from Kenyon College and an MBA from Harvard University. In addition to the GenoLogics board, Mr. Waite currently serves on the boards of: Accelerator, Adapx, Complete Genomics, Limerick BioPharma, NanoString and Verdezyne. Mr. Waite is a board member of the of the Washington Technology Alliance. He is also a Trustee at Kenyon College and a member of the OHSU (Oregon Health Sciences University) BSIF Advisory Board. |
Hans Knapp, Partner and General Counsel, Yaletown Venture PartnersHans co-founded Yaletown Venture Partners and brings over 15 years of legal counsel, corporate governance, turn-around, and investing experience to the Yaletown team. Hans serves on the board of Yaletown portfolio companies Cogent Health Solutions, Redlen Technologies and Thetus, and manages Yaletown’s investments in Genologics and MixPo. In addition, as Yaletown’s General Counsel he directs our firm’s investment transactions, operations and legal affairs. Prior to Yaletown, Hans was Vice President of Investments and Corporate Counsel for Brigill Investments, a private Vancouver-based venture capital firm. Earlier in his career he practiced law in the commercial litigation group of Borden Ladner Gervais and held a prestigious judicial clerkship at British Columbia’s highest court, the BC Court of Appeal. A recipient of Business in Vancouver’s “Top 40 Under 40” award, Hans has B.A. and LLB degrees from the University of British Columbia and is called to the Bar of British Columbia. |
Maria Pacella, GrowthWorks CapitalMs. Pacella joined GrowthWorks Capital in April 2001. She previously worked for an investment bank in mergers and acquisitions across a variety of industries including financial services and technology. More recently, Ms. Pacella worked at an interactive media firm assisting the company in operational activities and strategic initiatives. Ms. Pacella has a degree in Business Administration and is a Chartered Financial Analyst. Ms. Pacella also serves on the board of Tap Solutions Inc. |
Michael Ball, GenoLogicsMichael has served as CEO at GenoLogics since the Company’s commercial launch of its LIMS solution in 2004. Michael has been instrumental to the success of GenoLogics, securing significant venture capital and building strategic relationships with key partners and customers in the life sciences industry. He brings 25 years of international experience in sales, marketing, and business development with technology companies ranging from start-ups to Fortune 500 firms. Michael spent five years in executive management with Creo Products (acquired by Kodak) as VP Business Development and VP European Sales and Service. During his time at Creo, the business grew from $70 million to $700 million in revenues and it conducted a highly successful IPO. Previously, he spent seven years at Digital Equipment Corp. (now part of HP) in sales and marketing. Michael serves on the Board of the Canary Foundation, the only non-profit organization in the United States that is devoted exclusively to the early detection of cancer. |
Steve HnatiukSteve has been active in the development and financing of emerging technology companies for more than 20 years. He co-founded Yaletown Venture Partners in 2001 and was active in building the firm and its portfolio until 2010. Today he is an Executive Limited Partner investor in Yaletown-managed funds alongside other technology industry executives and entrepreneurs, and major Canadian and US institutional investors. Prior to starting Yaletown, Steve established and built TD Bank’s technology financing group on the west coast of Canada, was an executive in the technology industry group of PwC, and began his career as a software engineer with Accenture. Steve is active on the boards of several venture-backed companies, one Crown Corporation, two non-profit foundations, serves as Vice President of the board of directors for Canada’s Venture Capital & Private Equity Association (CVCA), and is on the editorial boards of Business in Vancouver newspaper and Canadian Private Capital magazine. He is a graduate of the University of British Columbia and British Columbia Institute of Technology, magna cum laude. |
Tristan Orpin, Senior Vice President and Chief Commercial Officer, Illumina Inc.Tristan Orpin joined Illumina in December 2002 in the role of vice president of worldwide sales, and in January 2007 was promoted to senior vice president of commercial operations. Before joining Illumina, Tristan held positions at Sequenom including vice president of sales and marketing from August 2001 to November 2002 and director of sales and marketing from September 1999 to August 2001. For more than a decade prior Tristan served in several senior sales and marketing positions at Bio-Rad Laboratories. Tristan earned a B.S. in genetics and biochemistry with first class honors from the University of Melbourne. |